重新定义低级别浆液性卵巢癌的治疗标准。

IF 1.1 Q4 ONCOLOGY

Clinical Advances in Hematology & Oncology Pub Date : 2024-06-01

Beryl L Manning-Geist, Tal Cantor, Róisín E O'Cearbhaill, Rachel N Grisham

{"title":"重新定义低级别浆液性卵巢癌的治疗标准。","authors":"Beryl L Manning-Geist, Tal Cantor, Róisín E O'Cearbhaill, Rachel N Grisham","doi":"","DOIUrl":null,"url":null,"abstract":"Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated following a high-grade serous carcinoma paradigm, new data have called into question the utility of platinum retreatment, addressed the possibility of first-line hormonal treatment, and brought forth therapeutic options targeting the MAPK pathway and cyclin D kinase in low-grade tumors. Ongoing research efforts seek to leverage the unique features of low-grade serous carcinoma to refine treatment options for patients with this rare tumor subtype.","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Redefining the standard of care for low-grade serous ovarian cancer.\",\"authors\":\"Beryl L Manning-Geist, Tal Cantor, Róisín E O'Cearbhaill, Rachel N Grisham\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated following a high-grade serous carcinoma paradigm, new data have called into question the utility of platinum retreatment, addressed the possibility of first-line hormonal treatment, and brought forth therapeutic options targeting the MAPK pathway and cyclin D kinase in low-grade tumors. Ongoing research efforts seek to leverage the unique features of low-grade serous carcinoma to refine treatment options for patients with this rare tumor subtype.\",\"PeriodicalId\":51585,\"journal\":{\"name\":\"Clinical Advances in Hematology & Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Advances in Hematology & Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Advances in Hematology & Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

低级别浆液性癌是一种罕见的上皮性卵巢癌亚型，具有独特的临床、组织学和分子特征。对这一疾病亚型的进一步了解促使治疗方案取得了最新进展。虽然低级别浆液性癌历来按照高级别浆液性癌的模式进行治疗，但新的数据对铂类再治疗的效用提出了质疑，探讨了一线激素治疗的可能性，并提出了针对低级别肿瘤中 MAPK 通路和细胞周期蛋白 D 激酶的治疗方案。正在进行的研究工作旨在利用低分化浆液性癌的独特特征，完善这一罕见肿瘤亚型患者的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Redefining the standard of care for low-grade serous ovarian cancer.

Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated following a high-grade serous carcinoma paradigm, new data have called into question the utility of platinum retreatment, addressed the possibility of first-line hormonal treatment, and brought forth therapeutic options targeting the MAPK pathway and cyclin D kinase in low-grade tumors. Ongoing research efforts seek to leverage the unique features of low-grade serous carcinoma to refine treatment options for patients with this rare tumor subtype.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Advances in Hematology & Oncology ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal reaching more than 27,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology, including feature-length review articles, monthly columns consisting of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development, and clinical case studies with expert commentary. CAH&O also publishes industry-supported meeting highlights, clinical roundtable monographs, and clinical review supplements.